
LRMR Stock Forecast & Price Target
LRMR Analyst Ratings
Bulls say
Larimar Therapeutics is poised for significant growth driven by its novel CPP technology platform and the expected commercial launch of its lead product candidate, nomlabofusp, in 2026, with projections of sales reaching $356 million by 2030. The positive interim data from ongoing clinical trials indicates improvements in frataxin levels and safety profile, supporting the drug's therapeutic potential for Friedreich's ataxia, while demonstrating a promising increase in survival rates in preclinical models. The upcoming regulatory clarity and confirmatory trials scheduled for mid-2025 further strengthen Larimar’s outlook in the biotech market by potentially validating the efficacy and safety of their innovative treatment.
Bears say
Larimar Therapeutics Inc. faces significant challenges as a development-stage biotechnology company, notably its lack of profitability, which poses a considerable overhang on its stock outlook. Compounding this issue, the FDA's refusal to accept alternative surrogate endpoints for their lead product candidate creates hurdles in advancing through the regulatory process, while safety concerns regarding potential cardiac toxicity due to Frataxin overexpression present additional risks. Moreover, potential reimbursement challenges associated with high orphan drug pricing and the invasive nature of required cardiac biopsies further exacerbate the company's financial and operational uncertainties.
This aggregate rating is based on analysts' research of Larimar Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
LRMR Analyst Forecast & Price Prediction
Start investing in LRMR
Order type
Buy in
Order amount
Est. shares
0 shares